1180112-41-7

Upstream product

• 1312784-58-9 tert-butyl 4-amino-4-(2-hydroxyethyl)piperidine-1-carboxylate 
• 1333222-34-6 4-amino-4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 392331-78-1 tert-butyl 2-oxo-1,7-diazaspiro[3.5]nonane-7-carboxylate 

Relevant academic research and scientific papers

Synthesis method of 1,7-diazaspiro[3.5]nonane-7-tert-butyl formate

The invention provides a process synthesis method of 1,7-diazaspiro[3.5]nonane-7-tert-butyl formate. The synthesis method comprises the following five steps: 1, reacting a compound 1 with a bromine compound 2 and ammonium acetate by a one-pot method to obtain a compound 2; 2, reducing a compound 3 by using lithium borohydride to obtain a compound 4; 3, using triethylamine is used as alkali, and reacting the compound 4 with p-toluene sulfonyl chloride to generate a compound 5; 4, under the catalysis of potassium iodide, taking cesium carbonate as alkali, and carrying out ring closing on the compound 5 to generate a compound 6; and 5, under the action of magnesium chips, removing p-toluene sulfonyl from the compound 6 to obtain a compound 7. The method mainly solves the technical problem that no method suitable for industrial synthesis exists at present, and has the advantages that raw materials are easy to obtain, the total yield is high, and the method is suitable for industrial production.

Preparation method of tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate and oxalate thereof

The invention relates to the field of synthesis of medical intermediates, and particularly discloses tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate and oxalate thereof. The preparation method of tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate comprises the following steps: by taking N-tert-butyloxycarbonyl-4-piperidone, ethyl hydrogen malonate and ammonium acetate as initial raw materials, sequentially carrying out Mannich reaction, reduction reaction, halogenation, cyclization reaction and purification to obtain purified tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate. The preparation method disclosed by the invention is simple to operate and suitable for industrial mass production.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.